top of page

Oct 11

IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year

Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.

Recent Posts

PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model

Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC

Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page